



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

13/L-11c  
09-13-91  
Electron  
PATENT  
Our Docket: P31 8600

In re application of:  
Wayne A. Border  
Erkki I. Ruoslahti  
Serial No.: 07/416,656  
Filed: October 3, 1989  
For: INHIBITING TRANSFORMING  
GROWTH FACTOR B TO  
PREVENT ACCUMULATION OF  
EXTRACELLULAR MATRIX

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

RECEIVED  
SEP 12 1991  
Group Art Unit: 182  
Examiner: D. Saunders  
GROUP 180

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on 8/30/91  
Date

By Theresa A. Brown  
Theresa A. Brown, Reg. No. 32,547  
\_\_\_\_\_  
Date of Signature 8/30/91

RESPONSE

Sir:

In response to the Office Action mailed on July 3, 1991, Applicants request consideration of the following remarks.

Remarks

The application has been primarily examined for restriction purposes. The Examiner has restricted the claims into the following groups under 35 U.S.C. §121:

- |            |   |
|------------|---|
| Group I:   | Claims 2 and 7 directed to treatment methods with antibodies; |
| Group II:  | Claims 3 and 8 directed to treatment methods with PDGF;       |
| Group III: | Claims 4 and 9 directed to treatment methods with peptides;   |
| Group IV:  | Claims 11 and 12 directed to TGF- $\beta$ detection methods   |

Group V:           Claims 16-18 directed to antibodies and  
                  cells producing antibodies

Claims 1, 5, 6, 10 and 13-15 are regarded as generic treatment claims.

In a telephone conference with the Examiner to clarify the restriction requirement, the Examiner indicated that an initial election of the treatment claims, Group IV or Group V must be made. If the treatment claims are elected, then a further election of species from Groups I-III must be made.

Applicants respectfully traverse the restriction requirement and contend the claims are sufficiently related that a search of all claims in one application would not pose a serious burden on the Examiner.

In order to be fully responsive, Applicants elect the treatment claims. Thus, claims 1-10 and 13-15 remain pending in the application. Applicants also elect the species of Group I directed to antibodies for further prosecution.

The Examiner is invited to call the undersigned attorney if there are any questions relating to the above-identified application.

Respectfully submitted,

Date

8/30/91

Theresa A. Brown  
Theresa A. Brown  
Registration No. 32,547  
Telephone: (619) 535-9001  
Facsimile: (619) 535-8949

PRETTY, SCHROEDER,  
BRUEGEMANN & CLARK  
444 South Flower Street  
Suite 2000  
Los Angeles, California 90071